Literature DB >> 29296830

CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells.

Sylvain Meunier1, Catherine Menier1, Elodie Marcon1, Sébastien Lacroix-Desmazes2, Bernard Maillère1.   

Abstract

We investigated the frequency and subset origin of circulating factor VIII (FVIII)-specific CD4 T cells in healthy donors. Total CD4 T cells and purified CD4 T-cell subsets were stimulated with FVIII-loaded autologous dendritic cells and challenged for specificity in interferon-γ enzyme-linked immunospots. The number of specific T-cell lines allowed estimation of the frequency of T cells circulating in the blood of the donors. All the 16 healthy donors generated strong in vitro T-cell responses, leading to the generation of 154 FVIII-specific T-cell lines. The mean frequency of FVIII-specific CD4 T cells in healthy donors was similar to that of T cells specific for foreign antigens and greater than that of T cells specific for known immunogenic therapeutic proteins. Normal levels of endogenous FVIII in healthy donors therefore do not prevent a significant escape of FVIII-specific CD4 T cells from negative thymic selection. FVIII-specific T cells mainly originated from both the naïve and central memory cell subsets, but their frequencies remained low as compared with those of cells specific for foreign antigens in immunized donors. The observation of a spontaneous generation of FVIII-specific memory T cells without a global expansion suggests peculiar peripheral tolerance mechanisms to FVIII in healthy donors.

Entities:  

Year:  2017        PMID: 29296830      PMCID: PMC5728100          DOI: 10.1182/bloodadvances.2017008706

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  27 in total

1.  HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P.

Authors:  R A Ettinger; E A James; W W Kwok; A R Thompson; K P Pratt
Journal:  Haemophilia       Date:  2010-05       Impact factor: 4.287

Review 2.  Acquired haemophilia A: a 2013 update.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Thromb Haemost       Date:  2013-09-05       Impact factor: 5.249

3.  Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential.

Authors:  Stéphanie Delluc; Gilles Ravot; Bernard Maillere
Journal:  Blood       Date:  2010-08-11       Impact factor: 22.113

4.  Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A.

Authors:  Antonino Cannavò; Carla Valsecchi; Isabella Garagiola; Roberta Palla; Pier Mannuccio Mannucci; Frits R Rosendaal; Flora Peyvandi
Journal:  Blood       Date:  2016-12-29       Impact factor: 22.113

Review 5.  Autoantibodies to factor VIII.

Authors:  Sébastien Lacroix-Desmazes; Namita Misra; Jagadeesh Bayry; Dipika Mohanty; Srini V Kaveri; Michel D Kazatchkine
Journal:  Autoimmun Rev       Date:  2002-02       Impact factor: 9.754

6.  Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.

Authors:  Shawn F J Whelan; Christoph J Hofbauer; Frank M Horling; Peter Allacher; Martin J Wolfsegger; Johannes Oldenburg; Christoph Male; Jerzy Windyga; Andreas Tiede; Hans Peter Schwarz; Friedrich Scheiflinger; Birgit M Reipert
Journal:  Blood       Date:  2012-12-12       Impact factor: 22.113

7.  Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII.

Authors:  M T Reding; D K Okita; B M Diethelm-Okita; T A Anderson; B M Conti-Fine
Journal:  J Thromb Haemost       Date:  2003-08       Impact factor: 5.824

8.  Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice.

Authors:  P S Ohashi; S Oehen; K Buerki; H Pircher; C T Ohashi; B Odermatt; B Malissen; R M Zinkernagel; H Hengartner
Journal:  Cell       Date:  1991-04-19       Impact factor: 41.582

9.  T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide.

Authors:  E A James; W W Kwok; R A Ettinger; A R Thompson; K P Pratt
Journal:  J Thromb Haemost       Date:  2007-12       Impact factor: 5.824

10.  Hierarchy of CD4 T cell epitopes of the ANRS Lipo5 synthetic vaccine relies on the frequencies of pre-existing peptide-specific T cells in healthy donors.

Authors:  Florence Anne Castelli; Natacha Szely; Alexis Olivain; Nicoletta Casartelli; Caroline Grygar; Aurélie Schneider; Aurore Besse; Yves Levy; Olivier Schwartz; Bernard Maillère
Journal:  J Immunol       Date:  2013-05-01       Impact factor: 5.422

View more
  12 in total

1.  TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity.

Authors:  Osman N Yogurtcu; Zuben E Sauna; Joseph R McGill; Million A Tegenge; Hong Yang
Journal:  AAPS J       Date:  2019-08-02       Impact factor: 4.009

Review 2.  Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia

Authors:  Richard S Blumberg; David Lillicrap
Journal:  Blood       Date:  2018-03-27       Impact factor: 22.113

3.  Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include Up-Regulated Innate Immune Modulators.

Authors:  Ahmad Faisal Karim; Anthony R Soltis; Gauthaman Sukumar; Christoph Königs; Nadia P Ewing; Clifton L Dalgard; Matthew D Wilkerson; Kathleen P Pratt
Journal:  Front Immunol       Date:  2020-06-12       Impact factor: 7.561

Review 4.  Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?

Authors:  Aditi Varthaman; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2018-12-04       Impact factor: 9.941

Review 5.  Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1.

Authors:  Davide Matino; Sajjad Afraz; George Zhao; Paul Tieu; Marco Gargaro; Francesca Fallarino; Alfonso Iorio
Journal:  Front Immunol       Date:  2020-04-15       Impact factor: 7.561

Review 6.  Tolerating Factor VIII: Recent Progress.

Authors:  Sebastien Lacroix-Desmazes; Jan Voorberg; David Lillicrap; David W Scott; Kathleen P Pratt
Journal:  Front Immunol       Date:  2020-01-10       Impact factor: 7.561

Review 7.  Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies.

Authors:  David W Scott; Kathleen P Pratt
Journal:  Front Immunol       Date:  2020-01-17       Impact factor: 8.786

Review 8.  Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays.

Authors:  Axel Ducret; Chloé Ackaert; Juliana Bessa; Campbell Bunce; Timothy Hickling; Vibha Jawa; Mark A Kroenke; Kasper Lamberth; Anaïs Manin; Hweixian L Penny; Noel Smith; Grzegorz Terszowski; Sophie Tourdot; Sebastian Spindeldreher
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

Review 9.  Drug and Chemical Allergy: A Role for a Specific Naive T-Cell Repertoire?

Authors:  Rami Bechara; Alexia Feray; Marc Pallardy
Journal:  Front Immunol       Date:  2021-06-29       Impact factor: 7.561

Review 10.  Specificity of the T Cell Response to Protein Biopharmaceuticals.

Authors:  Sylvain Meunier; Marie de Bourayne; Moustafa Hamze; Aurélien Azam; Evelyne Correia; Catherine Menier; Bernard Maillère
Journal:  Front Immunol       Date:  2020-07-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.